Erratum to: Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status

Malkov, Serghei; Shepherd, John; Scott, Christopher G.; Tamimi, Rulla M.; Ma, Lin; Bertrand, Kimberly A.; Couch, Fergus J.; Jensen, Matthew R.; Mahmoudzadeh, Amir Pasha; Fan, Bo; Norman, Aaron D.; Brandt, Kathleen R.; Pankratz, V. Shane; Vachon, Celine M.; Kerlikowske, Karla

doi:10.1186/s13058-016-0797-y

Cited by 52 publications

(45 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been previously reported that parity is differentially associated with breast cancer subtypes—in particular, that parous women are more likely to have TNBC than luminal A breast cancers ( 22 ). However, we found that high parity was prognostic of poor outcomes, when tumor size and nodal status were controlled for, but only in luminal B-like (HER2 negative) subtype cancers.…”

Section: Discussionmentioning

confidence: 99%

High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study

et al. 2020

View full text Add to dashboard Cite

While breast cancer prognoses are generally good, different molecular subtypes are known to have varying outcomes. Previous studies using breast cancer registries have suggested that high parity may be an adverse prognostic factor in luminal breast cancer, but breast cancer subtype definitions have varied and there have been few prospective studies. We therefore collected prospective data from patients diagnosed with early breast cancer at a single institution and followed them for a median of 8.5 years. All patients (N = 594) were treated according to Finnish national guidelines using modern treatment modalities in a Finnish university hospital. Clinicopathological surrogates of the intrinsic breast cancer subtypes were updated to match European Society for Medical Oncology 2015 Early Breast Cancer Clinical Practice Guidelines. The overall 10-year breast cancer-specific survival (BCSS) was 91.4%, with the longest 10-year BCSS observed in luminal Alike cancers (97.9%) and the worst in luminal B-like (HER2 positive) cancers (80.6%). Parity of ≥ 5 deliveries was also associated with poor BCSS (univariate P = 0.0020). However, when the subtypes were assessed separately in a multivariate analysis that included tumor size and nodal status, high parity remained significant only in luminal B-like (HER2 negative) cancers (HR = 2.63; 95% confidence interval = 1.04-6.62; P = 0.040). Our results suggest excellent overall 10-year BCSS but indicate that high parity is an adverse prognostic factor in luminal B-like (HER2 negative) breast cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Dovitinib was then evaluated in association with fulvestrant in postmenopausal patients with HER2-enriched or ER+ breast cancer. Despite the promising clinical activity, this trial was ended early due to the slow enrollment of the FGF-amplified subgroup (NCT01528345) [ 121 ]. The non-selective inhibitor named Lucitanib (E3810), which blocks the activity of VEGFR1-3 and FGFR1-2, has been tested in a phase II clinical study involving metastatic breast cancer patients with or without FGFR1 amplification.…”

Section: Therapeutic Targeting Of the Fgf/fgfr Axis In Breast Cancmentioning

confidence: 99%

“…Several reports have also highlighted the role of the FGF/FGFR system in the functional liaison between breast cancer cells and the surrounding tumor stroma [ 20 , 21 ]. Preclinical and clinical studies have indeed provided important hints on the feasibility of targeting FGFR in a novel anti-tumor strategy, at least in the subset of breast cancer patients harboring FGFR abnormalities [ 23 , 76 , 116 , 121 , 123 ]. On the other hand, the clinical trials described may evidence that considerable attention has been recently shifted to the usefulness of anti-FGFR drugs in combination with other chemotherapeutic agents [ 131 ].…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives

Santolla

Maggiolini

2020

Cancers

View full text Add to dashboard Cite

One of the major challenges in the treatment of breast cancer is the heterogeneous nature of the disease. With multiple subtypes of breast cancer identified, there is an unmet clinical need for the development of therapies particularly for the less tractable subtypes. Several transduction mechanisms are involved in the progression of breast cancer, therefore making the assessment of the molecular landscape that characterizes each patient intricate. Over the last decade, numerous studies have focused on the development of tyrosine kinase inhibitors (TKIs) to target the main pathways dysregulated in breast cancer, however their effectiveness is often limited either by resistance to treatments or the appearance of adverse effects. In this context, the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging transduction pathway and therapeutic target to be fully investigated among the diverse anti-cancer settings in breast cancer. Here, we have recapitulated previous studies dealing with FGFR molecular aberrations, such as the gene amplification, point mutations, and chromosomal translocations that occur in breast cancer. Furthermore, alterations in the FGF/FGFR signaling across the different subtypes of breast cancer have been described. Next, we discussed the functional interplay between the FGF/FGFR axis and important components of the breast tumor microenvironment. Lastly, we pointed out the therapeutic usefulness of FGF/FGFR inhibitors, as revealed by preclinical and clinical models of breast cancer.

show abstract

“…Previous studies have shown that reproductive factors, such as parity, number of pregnancies, age at menarche, and age at first birth, were related to the risk of breast cancer subtypes [23] , [24] , but the association between these variables and tumor grade was still controversial [13] , [16] . In the current study, we investigated the influence of reproductive factors, such as the number of births, number of pregnancies, and age at menarche, on tumor grade.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients

Zheng

Tan

Fan

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE: Breast cancer is now recognized as a clinically heterogeneous disease with a wide spectrum of epidemiological and clinicopathologic features. We aimed to evaluate whether epidemiological and clinicopathologic features are associated with the histological tumor grade of breast carcinomas in Western China. METHODS: We retrospectively collected data from the Western China Clinical Cooperation Group and assessed associations between clinicopathologic factors and histological tumor grade in 8619 female breast cancer patients. Patients were divided into two groups: Group I (tumor grade I/II) and Group II (tumor grade III). Univariable analysis and multivariable logistic regression models were used to analyze the relationships between clinicopathologic factors and tumor grade. RESULTS: Patients presenting with positive axillary lymph nodes, large tumor size (>2 cm), lymphovascular invasion, hormone receptor negativity, human epidermal growth factor receptor 2 (HER-2) positivity, and triple negativity tended to have an increased risk of a high tumor grade. However, the number of pregnancies or births was inversely correlated with the risk of a high tumor grade. In addition, patients presenting with grade III tumors were more likely to receive aggressive treatment, such as adjuvant chemotherapy, anti–HER-2 therapy, and level III axillary lymph node dissection. CONCLUSIONS: Our results suggested that several clinicopathologic factors were associated with high tumor grade of breast cancer patients in Western China.

show abstract

Erratum to: Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status

Cited by 52 publications

References 1 publication

High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study

High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives

Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients

Contact Info

Product

Resources

About